- Policy
- Koselugo is the only non-reimbursed drug among 21
- by Lee, Tak-Sun Jan 3, 2023 05:41am
- The Health Insurance Review and Assessment Service’s Drug Reimbursement Evaluation Committee (DREC) reviewed 21 items last year, among which only 1 failed to pass deliberations and be determined non-reimbursable. This non-reimbursed drug was the neurofibroma treatment ‘Koselugo Cap.’ Among the other 20, 9 were recognized to be adequate for
- Opinion
- [Reporter's view] Expectations for Revlimid
- by Eo, Yun-Ho Jan 3, 2023 05:41am
- The maintenance therapy of Revlimid, a treatment for multiple myeloma, has been on the insurance benefit list since the new year of 2023 after more than four years of waiting. Revlimid maintenance therapy has simply had a lot of ups and downs. Since 2019, BMS Pharmaceutical Korea has actively carried out the registration process, but there ha
- Company
- SK Chemical introduces Lou Gehrig's treatment Teglutik
- by Lee, Seok-Jun Jan 3, 2023 05:41am
- On the 2nd, SK Chemical announced it will be launching ‘Teglutik,’ a Lou Gehrig's disease treatment that was developed by the Italian pharmacuetical company, Italfarmaco, in Korea. The drug is indicated for the treatment of amyotrophic lateral sclerosis (ALS), a progressive neuromuscular disease that is also referred to as Lou Gehrig's d
- Policy
- The fast track of tx for serious dz without a substitute
- by Lee, Tak-Sun Jan 3, 2023 05:40am
- Prior consultations will be newly established before the main negotiation to quickly register anticancer drugs without alternative drugs and treatments for severe and rare diseases. Accordingly, the negotiation period for the drug will be reduced from 60 days to 30 days. The NHIS announced on the 30th some revisions to the drug price negotiation
- Policy
- Will Koselugo, a new neurofibroma drug be reimbursed next ye
- by Lee, Tak-Sun Jan 3, 2023 05:40am
- "Koselugo (Selumetinib, AstraZeneca), the first drug used for childhood neurofibromatosis, a rare disease, is stepping up its challenge." Although he had a hard time at the HIRA in March, efforts to register health insurance have continued since then, such as supplementing data and reapplying for benefits. Starting next year, expectations fo
- Policy
- Largest-ever drug pricing reeval to be conducted this year
- by Kim, Jung-Ju Jan 2, 2023 06:04am
- The health and pharmaceutical industry is busy preparing various systems and policies for the new year. The reimbursement adequacy reevaluations for listed drugs that had been initiated as a pilot project on choline alfoscerate products settled as an annual policy project and are expected to start full-scale reevaluations on previously not
- Policy
- SK Chemicals Riluzole is listed
- by Lee, Tak-Sun Jan 2, 2023 06:04am
- Only tablet type is available for Riluzole, and suspension type is expected to be an alternative for patients with difficulty in swallowing. According to industries on the 1st, SK Chemical's Teglutik Suspension was listed at 134,970 won per bottle. Riluzole, the main ingredient of Teglutik, is used in the treatment of Amyotrophic Lateral S
- Policy
- High conc Ultomiris Inj 100mg/mL also approved in Korea
- by Kim, Jung-Ju Jan 2, 2023 06:04am
- Handok received marketing authorization for the orphan drug ‘Ultromiris 100mg/mL(ravulizumab)’ that is used to treat Paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uraemic syndrome (aHUS) and made a step towards supplying the drug in Korea. On the 28th, the Ministry of Food and Drug Safety announced that it had grante
- Product
- How is the non-face-to-face tx/delivery going overseas?
- by Jan 2, 2023 06:04am
- With the platform industry and the medical community preparing first ahead of the institutionalization of non-face-to-face treatment next year, calls for measures to be prepared for drug delivery are gaining momentum. A recent study report titled "Non-face-to-face treatment prerequisites" by the Korean Medical Association's Medical Policy Ins
- Company
- U.S. first possible NASH therapy
- by Jan 2, 2023 06:04am
- The U.S. Madrigal Pharmaceuticals has succeeded in phase 3 clinical trials of Resmetirom, a new drug candidate for non-alcoholic fatty hepatitis (NASH). When new drugs are approved, Resmetirom appears as the first NASH treatment aimed at the 33 trillion won market. Yuhan Corporation, Hanmi Pharmaceutical, and LG Chem are also speeding up the
